Treatment of Nocturia in Interstitial Cystitis/Bladder Pain Syndrome
Introduction to Treatment Guidelines
- The American Urological Association recommends beginning with behavioral modifications and dietary elimination, then escalating systematically through oral medications, intravesical therapies, and reserving advanced interventions only for refractory cases 1, 2, 3
First-Line: Behavioral and Dietary Interventions
- Restrict fluid intake in the evening hours to reduce nighttime urine production and decrease nocturia episodes, as recommended by the American Urological Association 1, 2, 4
- Increase daytime hydration to dilute urinary irritants while limiting evening fluids, as suggested by the American Urological Association 1, 2, 4
- Eliminate coffee, citrus products, and spicy foods—all known bladder irritants that worsen nocturia, as recommended by the Interstitial Cystitis Association 3, 5
- Implement a systematic elimination diet to identify personal trigger foods that exacerbate nighttime symptoms, as suggested by the American Urological Association 1, 2, 6
Second-Line: Oral Medications
- Cimetidine specifically improves nocturia in IC/BPS patients with Grade B evidence and no reported adverse events, making it a preferred oral medication choice when nocturia is the predominant symptom requiring treatment, as recommended by the American Urological Association 1, 2
- Amitriptyline is superior to placebo for IC/BPS symptoms with Grade B evidence, though adverse effects are common and may compromise quality of life, as noted by the American Urological Association 1, 2, 6
Third-Line: Intravesical Therapies
- Heparin intravesical therapy repairs the damaged glycosaminoglycan layer and provides clinically significant symptom improvement, as recommended by the Interstitial Cystitis Association 3, 5
Critical Pain Management Principles
- Initiate multimodal pain management approaches throughout all treatment phases, as recommended by the American Urological Association 1, 2, 6, 4, 3
- Strongly prefer non-opioid alternatives due to the chronic nature of IC/BPS and the global opioid crisis, as suggested by the American Urological Association 1, 2, 6, 4